Opendata, web and dolomites

DECODE SIGNED

reDucing the health and Economic COst of Diagnostic uncErtainty: launch and randomized control trial of the first validated bacterial versus viral test

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DECODE project word cloud

Explore the words cloud of the DECODE project. It provides you a very rough idea of what is the project "DECODE" about.

antimicrobial    commercially    burden    routine    instances    suspected    dach    hospitalization    pioneering    randomized    settings    platform    capillary    efforts    care    release    validated    runs    bacterial    clinically    validation    blind    15    inappropriate    risk    concurrently    trial    bv    externally    broad    regulatory    trade    conduct    infection    children    utility    body    double    distinguishing    clinical    500    global    decide    enrolling    compatible    expand    solution    health    applicability    gap    poc    biomarkers    fight    healthcare    acute    suitable    misuse    indistinguishable    avoidable    workflow    samples    threats    minutes    data    diagnostic    outcomes    gather    immune    constraints    clinician    initiate    serum    resistance    viral    thousands    multicentre    reducing    elevated    leads    market    economic    diagnostics    tool    share    world    patients    actionable    cleared    problem    decodes    key    rct    complete    gaps    memed    amr    blood    superiority    confidence    inferior    primary    routinely    clinicians    reduces    infections    patient    demonstrated    decode   

Project "DECODE" data sheet

The following table provides information about the project.

Coordinator
MEMED DIAGNOSTICS LTD 

Organization address
address: NAHUM HETH STREET 5
city: TIRAT CARMEL
postcode: 39120
website: www.me-med.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙571˙427 €
 EC max contribution 2˙499˙999 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEMED DIAGNOSTICS LTD IL (TIRAT CARMEL) coordinator 2˙499˙999.00

Map

 Project objective

Problem: Clinicians routinely face diagnostic uncertainty because acute infections are often clinically indistinguishable and today’s diagnostics have constraints. This uncertainty leads to inappropriate patient management, including antimicrobial misuse and avoidable hospitalization. The associated health economic burden are inferior patient outcomes, elevated costs, and antimicrobial resistance (AMR), one of the top 10 threats to global health. Potential solution: In many instances, the clinician only needs to know with confidence if the infection is bacterial or viral to decide how to manage a patient suspected to have an acute infection. We have developed and validated MeMed BV™ - a pioneering test for distinguishing between bacterial and viral infections that decodes the body’s immune response to infection. BV™ has been both double-blind and externally validated in clinical studies enrolling thousands of patients and demonstrated superiority to biomarkers in routine use. Concurrently, we have developed Key™, an easy-to-use POC platform that runs BV™ in 15 minutes. Gap: Broad impact of BV™ and market share require high-risk efforts to address the following major gaps: 1. Real world evidence of usage and impact on workflow. 2. Validation of clinical utility in a randomized control trial (RCT). 3. Expand applicability to primary care settings. Proposed objectives: 1. To initiate market release in DACH and gather real world data. 2. To conduct a multicentre RCT enrolling 500 children. 3. Complete development of BV™ compatible with capillary blood. Impact: DECODE will take BV™ on Key™ from a test regulatory cleared for use to one that is available commercially and adopted in routine care, has validated clinical utility and is suitable for both serum and capillary blood samples. By providing an actionable tool that reduces diagnostic uncertainty, this project will improve patient outcomes while reducing healthcare costs and help fight AMR.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DECODE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DECODE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More